New antibody drug ZMA001 enters first human safety trial
NCT ID NCT05967299
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 1 trial tests the safety of a new drug called ZMA001 in 96 healthy adults. ZMA001 is a monoclonal antibody designed to reduce lung damage in pulmonary arterial hypertension (PAH), a serious condition. Participants receive a single dose of the drug or placebo and are monitored for about 16 weeks. This is the first time ZMA001 is given to humans.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ZMA001 (a monoclonal antibody)
What this could lead to
If successful, this could lead to a new treatment for pulmonary arterial hypertension (PAH), a serious lung disease.
What could go wrong
This is a very early phase 1 trial in healthy people, not patients. It only tests safety and dosing, not whether the drug works for PAH. Many drugs fail in later stages.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION (PAH) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••